Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Windtree Therapeutics ( (WINT) ).
On September 2, 2025, Steven G. Simonson, M.D. resigned from his position as Senior Vice President and Chief Medical Officer at Windtree Therapeutics, Inc., effective immediately.
Spark’s Take on WINT Stock
According to Spark, TipRanks’ AI Analyst, WINT is a Underperform.
Windtree Therapeutics faces significant financial challenges with no revenue and considerable net losses, severely impacting its financial health and stability in the biotechnology sector. The technical analysis suggests bearish momentum, aligning with the weak financials. The negative P/E ratio and lack of dividends make valuation unattractive. Recent corporate events provide a minor positive outlook, but overall, the stock presents considerable risks with limited upside potential without a substantial change in financial performance or market conditions.
To see Spark’s full report on WINT stock, click here.
More about Windtree Therapeutics
Average Trading Volume: 12,371,345
Technical Sentiment Signal: Sell
Current Market Cap: $2.14M
For detailed information about WINT stock, go to TipRanks’ Stock Analysis page.